Clinical trials: Central Vein Obstruction
Oncology, Medical, Hematologic Disease
Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters
Long-term central venous access devices are considered as safe for the administration of medication as chemotherapy, but are also used for blood sampling.
- Trial name
- NCT00994136
- Testing
- normal saline
- Where
- Belgium
- Volunteers
- 1,100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatic Veno-Occlusive Disease
European VOD Registry
Following the licencing of a new drug, Defitelio®, indicated for the treatment of severe Veno-Occlusive Disease of the liver (sVOD), a rare but serious complication of haematopoietic stem cell transplantation (HSCT), as a…
- Trial name
- NCT03032016
- Where
- 53 sites in France, Italy and 2 more
- Volunteers
- 176 people
- Sponsor
- Jazz Pharmaceuticals
Age Related Macular Degeneration, Central Retinal Vein Occlusion
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
Aflibercept is FDA approved and the same molecule is available as hyperosmolar for oncology (cost 800 USD for 4ml) and isoosmolar for Ophthalmology (cost 1,770 USD for 0.05ml injection).
- Trial name
- ZIV (NCT02173873)
- Testing
- ziv-aflibercept drug
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Central Retinal Vein Occlusion
Bevacizumab for Central Retinal Vein Occlusion Study
Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity.
- Trial name
- NCT00906685
- Testing
- bevacizumab
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Anders Kvanta
Retinal Vein Occlusion
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT00403039
- Testing
- Ranibizumab (Lucentis )
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Retinal Vein Occlusion
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of CRVO.
- Trial name
- JPMS-CRVO (NCT02040220)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 385 people
- Sponsor
- Bayer
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Non-Ischemic Central Retinal Vein Occlusion With Macular Edema
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old
- Trial name
- NCT05282420
- Testing
- intravitreal injection of Ranibizumab, intravitreal injection of Aflipercept, Ranibizumab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- South Valley University
Central Retinal Vein Occlusion, Choroidal Neovascularization
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
This is a research study to evaluate the effects of repeated intravitreal injections on bacteria around the eye.
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Trial name
- NCT01531842
- Testing
- Conj flora Antibiotic resistance
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mid Atlantic Retina
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Pediatric Congestive Heart Failure, Congestive Heart Failure
A Clinical Study Used to Estimate Central Venous Pressure Non-invasively Using Occlusion Pressure
The purpose of this study is to collect different measurements using a method called peripheral venous pressure (PVP). PVP checks the pressure in the veins in the arms or legs.
- Trial name
- CV-PRO (NCT07583680)
- Volunteers
- 30 people
- Sponsor
- Le Bonheur Children's Hospital
Macular Edema, Central Retinal Vein Occlusion
Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
- Trial name
- MECROV (NCT00566761)
- Testing
- bevacizumab and triamcinolone
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Thrombosis
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
- Trial name
- NCT00265005
- Testing
- alteplase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Louisville
Central Retinal Vein Occlusion
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion.
- Trial name
- NCT01178697
- Testing
- Bevasizumab, Triamcinolone Acetonide
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Total Anomalous Pulmonary Venous Connection
Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection
Total anomalous pulmonary venous connection (TAPVC) is a complex congenital heart disease, requiring surgical repair. Pulmonary venous obstruction (PVO) is the major complication, with limited effective reinterventions and poor…
- Trial name
- NCT04241380
- Testing
- Anticoagulant Solutions, No anticoagulant solutions, Anticoagulant management
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangdong Provincial People's Hospital
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients
In this research study we want to learn more about a study drug, tetrasodium sodium EDTA (Kitelock™) for maintaining the patency (blood flow) through a central venous catheter.
- Trial name
- NCT04559334
- Testing
- Tetrasodium EDTA Catheter Lock Solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston Children's Hospital
Pediatric Intestinal Failure
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children…
- Trial name
- NCT05879835
- Testing
- KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- SterileCare Inc.
Intensive Care Units, Neonatal, Misadventures to Patients During Surgical and Medical Care
SEPREVEN: a Stepped-wedge Randomised Controlled Trial
Adverse events are frequent in Neonatal Intensive Care Units' (NICU) patients and account for a high morbidity and mortality. Possible severe adverse events are central line associated bloodstream infections (CLABSI), ventilator…
- Conditions
- Intensive Care Units, Neonatal, Misadventures to Patients During Surgical and Medical Care, Catheter-related Bloodstream Infection (CRBSI) Nos, Quality of Healthcare
- Trial name
- SEPREVEN (NCT02598609)
- Testing
- Education program for NICU caregivers
- Where
- 12 sites in France
- Volunteers
- 8,000 people
- Sponsor
- Dr Caeymaex Laurence
Childhood Cancer, Central Venous Catheters
Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
The primary hypothesis of this study is that occult catheter-related DVT in children with cancer is common and directly contributes to development of serious catheter complications, specifically bacteremia/fungemia and/or…
- Conditions
- Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection
- Trial name
- DVT (NCT00633061)
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- University of Texas Southwestern Medical Center